Sun Pharmaceutical Industries appoints Dheeraj Sinha as Executive Vice President, Chief Information Officer

Published On 2024-04-04 06:00 GMT   |   Update On 2024-04-04 15:47 GMT
Advertisement

Mumbai: Sun Pharmaceutical Industries Limited has appointed Dheeraj Sinha as Executive Vice President and Chief Information Officer effective from April 3, 2024.

Sinha replaces Anil Rao, Senior Vice President and Chief Information Officer.  Anil Rao resigned due to personal reasons and his last working day with the Company will be April 30, 2024.

"This is to inform that Mr. Dheeraj Sinha is appointed as Executive Vice President and Chief Information Officer effective from April 3, 2024," the Company stated in a BSE filing.

Advertisement
Dheeraj Sinha was associated with JSW as EVP & Group Chief Information Officer for 8+ years. In a career spanning over three decades, he has been associated with JSW Group, Apollo Tyres, Infovergix Technologies, UMIT Ltd. and Modi Xerox. Prior to JSW, he was the Group CIO and Global Supply Chain Head with Apollo Tyres for over 12 years,
Sinha is MBA in Finance & Operations from MDI and B.Tech. in Electronics and Communication Engineering from Birla Institute of Technology, Mesra and has undergone Strategic Leadership Programs from Brown University and IMD Laussane, Switzerland. Also, he is currently pursuing his Ph.D. from Narsee Monjee University, Mumbai.
Medical Dialogues had earlier reported the retirement of Sailesh Trambaklal Desai from Sun Pharma's Board of Directors, as he completed his term as a Director on March 31, 2024.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Sun Pharma gets Australian regulatory nod for acne vulgaris treatment Winlevi

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News